

# **FOI 1908 - Attachment 1**

Number of patients who received a homecare delivery service of drug and/or nurse service up to 3 October 2019

| Drug name                              | Total |
|----------------------------------------|-------|
| Alecensa-Alectinib                     | *     |
| Amgevita-Adalimumab                    | 97    |
| Benepali-Etanercept                    | 283   |
| Cimzia-Certolizumab Pegol              | 66    |
| Cosentyx-Secukinumab                   | *     |
| Cosentyx-Secukinumab                   | 6     |
| Cosentyx-Secukinumab                   | 54    |
| Crysvita-Burosumab                     | *     |
| Daklinza-Daclatasvir                   | *     |
| Dupixent-Dupilumab                     | 26    |
| Enbrel-Etanercept                      | 59    |
| Epclusa-Sofosbuvir/Velpatasvir         | 44    |
| Erelzi-Etanercept                      | 34    |
| Esbriet-Pirfenidone                    | 42    |
| Exviera-Dasabuvir                      | *     |
| Forsteo-Teriparatide                   | 145   |
| Glivec-Imatinib                        | *     |
| Harvoni-Ledipasvir/Sofosbuvir          | 53    |
| Humatrope-Somatropin                   | *     |
| Humira-Adalimumab                      | 161   |
| Imbruvica-Ibrutinib                    | 41    |
| Imraldi-Adalimumab                     | 119   |
| Infliximab-Inflectra                   | *     |
| Kineret-Anakinra                       | *     |
| Maviret-glecaprevir/pibrentasvir       | 40    |
| Metoject-Methotrexate                  | 28    |
| Nordiflex-Somatropin                   | *     |
| Norditropin-Somatropin                 | 10    |
| Nucala-Mepolizumab                     | *     |
| Ocaliva-Obeticholic Acid               | 10    |
| Ofev-Nintedanib                        | 38    |
| Olumiant-Baricitinib                   | 75    |
| Orencia-Abatacept                      | 93    |
| Otezla-Apremilast                      | 63    |
| Repatha-Evolocumab                     | *     |
| Risperdal-Risperidone                  | 59    |
| Roactemra-Tocilizumab                  | 54    |
| Ruxolitinib-Jakavi                     | *     |
| Saizen-Somatropin                      | *     |
| Simponi-Golimumab                      | 22    |
| Soliris-Eculizumab                     | *     |
| Sovaldi-Sofosbuvir                     | 12    |
| Stelara-Ustekinumab                    | 78    |
| Sutent-Sunitinib                       | *     |
| Tagrisso-Osimertinib                   | *     |
| Taltz-Ixekinumab                       | *     |
| Tarceva-Erlotinib                      | *     |
| Trevicta-Paliperidone                  | 6     |
| Venclyxto-Venetoclax                   | *     |
| Viekirax-Ombitasvir,Partaprevir and Ri | *     |
| Xeplion-Paliperidone                   | 114   |
| Xtandi-Enzalutamide                    | *     |
| Zepatier-Elbasvir, Grazoprevir         | *     |
| Zomacton-somatropin                    | *     |

| Therapy/Clinical area      | Total |
|----------------------------|-------|
| Cardiology                 | *     |
| CMH                        | *     |
| CMHT                       | 109   |
| Dermatology                | 189   |
| Endocrinology              | *     |
| Gastro/Meds                | *     |
| Gastroenterology           | 234   |
| Gastroenterology/Heptology | *     |
| Gerontology                | 80    |
| Haematology                | 48    |
| HCV                        | 10    |
| Heptology                  | 90    |
| Medical                    | *     |
| N/A                        | 188   |
| Oncology                   | 15    |
| Paediatrics                | 14    |
| Paediatricsiatrics         | *     |
| Respiratory                | 83    |
| Rheumatology               | 908   |